Who is eligible for clinical trial NCT06608927?

Participants must meet protocol criteria for Metastatic Pancreatic Ductal Adenocarcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06608927 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-29

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (NCT06608927)

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Arcus Biosciences, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

Who can join: Review the eligibility criteria below.

Location: Research Site — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (111 Sites)

Showing the first 25 of 111 sites.

Research Site — Phoenix, Arizona
Research Site — Tucson, Arizona
Research Site — La Jolla, California
Research Site — Los Alamitos, California
Research Site — Los Angeles, California
Research Site — Roseville, California
Research Site — San Francisco, California
Research Site — Santa Monica, California
Research Site — Denver, Colorado
Research Site — New Haven, Connecticut
Research Site — Jacksonville, Florida
Research Site — Miami, Florida
Research Site — Atlanta, Georgia
Research Site — Atlanta, Georgia
Research Site — Arlington Heights, Illinois
Research Site — Chicago, Illinois
Research Site — Indianapolis, Indiana
Research Site — Wichita, Kansas
Research Site — Baton Rouge, Louisiana
Research Site — Ann Arbor, Michigan
Research Site — Grand Rapids, Michigan
Research Site — Minneapolis, Minnesota
Research Site — Rochester, Minnesota
Research Site — Hattiesburg, Mississippi
Research Site — Kansas City, Missouri

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Pancreatic Ductal Adenocarcinoma

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy — Middletown, New Jersey
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) — Basking Ridge, New Jersey
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — Washington D.C., District of Columbia
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma — Los Angeles, California
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma — St Louis, Missouri

Explore by condition: All Metastatic Pancreatic Ductal Adenocarcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗